Anesthesia for suboccipital craniotomy in a patient with lymphangioleiomyomatosis: a case report.
Case Rep Pulmonol., 2012:804789 (2012)
Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
Mol. Ther., Jan;20(1):37-45 (2012)
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
Neuro-oncology., Feb;14(2):132-44 (2012)
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
J. Natl. Cancer Inst., Jan;104(1):42-55 (2012)
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Mol. Ther., Jun;16(6):1041-7 (2008)
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.
Proc. Natl. Acad. Sci. U.S.A., Mar;106(12):4822-7 (2009)
Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells.
Clin. Cancer Res., Dec;14(23):7711-6 (2008)
Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.
Cancer Gene Ther., Jul;16(7):551-60 (2009)
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
Cancer Res., Apr;69(8):3472-81 (2009)
Genetic determinants of hearing loss associated with vestibular schwannomas.
Otol. Neurotol., Aug;30(5):661-7 (2009)
Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.
Gene Ther., Dec;16(12):1477-82 (2009)
Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.
Gene Ther., Jun;17(6):805-10 (2010)
Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.
Cancer Res., May;70(10):3890-5 (2010)
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
Clin. Cancer Res., Jun;17(11):3686-96 (2011)
Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
BMC Biotechnol., 6:40 (2006)
Oncolytic viral therapies - the clinical experience.
Oncogene., Nov;24(52):7802-16 (2005)
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Mol. Ther., Dec;14(6):789-97 (2006)
Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Cancer Res., Oct;66(20):10127-35 (2006)
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Clin. Cancer Res., Nov;12(22):6791-9 (2006)
Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Cancer Res., Jan;67(2):440-4 (2007)